A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer.
De Bleser E, Willems R, Decaestecker K, Annemans L, De Bruycker A, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, De Meerleer G, Ost P, Bultijnck R.
De Bleser E, et al. Among authors: de meerleer g, de bruycker a.
Cancers (Basel). 2020 Jan 4;12(1):132. doi: 10.3390/cancers12010132.
Cancers (Basel). 2020.
PMID: 31947974
Free PMC article.